Ensysce Biosciences Q2 EPS $(0.22) Beats $(0.39) Estimate, Sales $181.80K Miss $300.00K Estimate
Author: Benzinga Newsdesk | August 14, 2024 04:49pm
Ensysce Biosciences (NASDAQ:
ENSC) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.39) by 43.59 percent. This is a 77.55 percent increase over losses of $(0.98) per share from the same period last year. The company reported quarterly sales of $181.80 thousand which missed the analyst consensus estimate of $300.00 thousand by 39.40 percent. This is a 62.93 percent decrease over sales of $490.47 thousand the same period last year.
Posted In: ENSC